Product: Phospho-TIE2 (Tyr992) Antibody
Catalog: AF2424
Description: Rabbit polyclonal antibody to Phospho-TIE2 (Tyr992)
Application: WB IHC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Chicken, Xenopus
Mol.Wt.: 160kDa; 126kD(Calculated).
Uniprot: Q02763
RRID: AB_2845437

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Zebrafish(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Chicken(100%), Xenopus(100%)
Clonality:
Polyclonal
Specificity:
Phospho-TIE2 (Tyr992) Antibody detects endogenous levels of TIE2 only when phosphorylated at Tyr992.
RRID:
AB_2845437
Cite Format: Affinity Biosciences Cat# AF2424, RRID:AB_2845437.
Conjugate:
Unconjugated.
Purification:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Angiopoietin 1 receptor; Angiopoietin-1 receptor; CD202b; CD202b antigen; Endothelial tyrosine kinase; Endothelium specific receptor tyrosine kinase 2; hTIE 2; hTIE2; Hyk; p140 TEK; Soluble TIE2 variant 1; Soluble TIE2 variant 2; Tek; tek tyrosine kinase; TEK tyrosine kinase endothelial; tek tyrosine kinase, endothelial; TIE 2; TIE2; TIE2_HUMAN; Tunica interna endothelial cell kinase; Tyrosine kinase with Ig and EGF homology domains 2; Tyrosine kinase with Ig and EGF homology domains-2; Tyrosine protein kinase receptor TEK; Tyrosine protein kinase receptor TIE 2; Tyrosine-protein kinase receptor TEK; Tyrosine-protein kinase receptor TIE-2; Venous malformations multiple cutaneous and mucosal; VMCM 1; VMCM; VMCM1;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
Q02763 TIE2_HUMAN:

Detected in umbilical vein endothelial cells. Proteolytic processing gives rise to a soluble extracellular domain that is detected in blood plasma (at protein level). Predominantly expressed in endothelial cells and their progenitors, the angioblasts. Has been directly found in placenta and lung, with a lower level in umbilical vein endothelial cells, brain and kidney.

Sequence:
MDSLASLVLCGVSLLLSGTVEGAMDLILINSLPLVSDAETSLTCIASGWRPHEPITIGRDFEALMNQHQDPLEVTQDVTREWAKKVVWKREKASKINGAYFCEGRVRGEAIRIRTMKMRQQASFLPATLTMTVDKGDNVNISFKKVLIKEEDAVIYKNGSFIHSVPRHEVPDILEVHLPHAQPQDAGVYSARYIGGNLFTSAFTRLIVRRCEAQKWGPECNHLCTACMNNGVCHEDTGECICPPGFMGRTCEKACELHTFGRTCKERCSGQEGCKSYVFCLPDPYGCSCATGWKGLQCNEACHPGFYGPDCKLRCSCNNGEMCDRFQGCLCSPGWQGLQCEREGIQRMTPKIVDLPDHIEVNSGKFNPICKASGWPLPTNEEMTLVKPDGTVLHPKDFNHTDHFSVAIFTIHRILPPDSGVWVCSVNTVAGMVEKPFNISVKVLPKPLNAPNVIDTGHNFAVINISSEPYFGDGPIKSKKLLYKPVNHYEAWQHIQVTNEIVTLNYLEPRTEYELCVQLVRRGEGGEGHPGPVRRFTTASIGLPPPRGLNLLPKSQTTLNLTWQPIFPSSEDDFYVEVERRSVQKSDQQNIKVPGNLTSVLLNNLHPREQYVVRARVNTKAQGEWSEDLTAWTLSDILPPQPENIKISNITHSSAVISWTILDGYSISSITIRYKVQGKNEDQHVDVKIKNATITQYQLKGLEPETAYQVDIFAENNIGSSNPAFSHELVTLPESQAPADLGGGKMLLIAILGSAGMTCLTVLLAFLIILQLKRANVQRRMAQAFQNVREEPAVQFNSGTLALNRKVKNNPDPTIYPVLDWNDIKFQDVIGEGNFGQVLKARIKKDGLRMDAAIKRMKEYASKDDHRDFAGELEVLCKLGHHPNIINLLGACEHRGYLYLAIEYAPHGNLLDFLRKSRVLETDPAFAIANSTASTLSSQQLLHFAADVARGMDYLSQKQFIHRDLAARNILVGENYVAKIADFGLSRGQEVYVKKTMGRLPVRWMAIESLNYSVYTTNSDVWSYGVLLWEIVSLGGTPYCGMTCAELYEKLPQGYRLEKPLNCDDEVYDLMRQCWREKPYERPSFAQILVSLNRMLEERKTYVNTTLYEKFTYAGIDCSAEEAA

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Xenopus
100
Zebrafish
100
Chicken
100
Rabbit
100
Dog
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q02763 As Substrate

Site PTM Type Enzyme
T115 Phosphorylation
N140 N-Glycosylation
S142 Phosphorylation
S164 Phosphorylation
N596 N-Glycosylation
Y697 Phosphorylation
Y816 Phosphorylation
Y860 Phosphorylation Q02763 (TEK)
Y897 Phosphorylation Q02763 (TEK)
Y899 Phosphorylation
Y976 Phosphorylation
Y992 Phosphorylation Q02763 (TEK)
T996 Phosphorylation
Y1048 Phosphorylation
Y1102 Phosphorylation Q02763 (TEK)
Y1108 Phosphorylation Q02763 (TEK)
Y1113 Phosphorylation
S1119 Phosphorylation

PTMs - Q02763 As Enzyme

Substrate Site Source
Q02763 (TEK) Y860 Uniprot
Q02763 (TEK) Y897 Uniprot
Q02763 (TEK) Y992 Uniprot
Q02763 (TEK) Y1102 Uniprot
Q02763 (TEK) Y1108 Uniprot

Research Backgrounds

Function:

Tyrosine-protein kinase that acts as cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. Required for normal angiogenesis and heart development during embryogenesis. Required for post-natal hematopoiesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of sprouting angiogenesis. ANGPT1 signaling triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Signaling is modulated by ANGPT2 that has lower affinity for TEK, can promote TEK autophosphorylation in the absence of ANGPT1, but inhibits ANGPT1-mediated signaling by competing for the same binding site. Signaling is also modulated by formation of heterodimers with TIE1, and by proteolytic processing that gives rise to a soluble TEK extracellular domain. The soluble extracellular domain modulates signaling by functioning as decoy receptor for angiopoietins. TEK phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1.

PTMs:

Proteolytic processing leads to the shedding of the extracellular domain (soluble TIE-2 alias sTIE-2).

Autophosphorylated on tyrosine residues in response to ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Autophosphorylation occurs in a sequential manner, where Tyr-992 in the kinase activation loop is phosphorylated first, followed by autophosphorylation at Tyr-1108 and at additional tyrosine residues. ANGPT1-induced phosphorylation is impaired during hypoxia, due to increased expression of ANGPT2. Phosphorylation is important for interaction with GRB14, PIK3R1 and PTPN11. Phosphorylation at Tyr-1102 is important for interaction with SHC1, GRB2 and GRB7. Phosphorylation at Tyr-1108 is important for interaction with DOK2 and for coupling to downstream signal transduction pathways in endothelial cells. Dephosphorylated by PTPRB.

Ubiquitinated. The phosphorylated receptor is ubiquitinated and internalized, leading to its degradation.

Subcellular Location:

Cell membrane>Single-pass type I membrane protein. Cell junction. Cell junction>Focal adhesion. Cytoplasm>Cytoskeleton. Secreted.
Note: Recruited to cell-cell contacts in quiescent endothelial cells (PubMed:18425120, PubMed:18425119). Colocalizes with the actin cytoskeleton and at actin stress fibers during cell spreading. Recruited to the lower surface of migrating cells, especially the rear end of the cell. Proteolytic processing gives rise to a soluble extracellular domain that is secreted (PubMed:11806244).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Detected in umbilical vein endothelial cells. Proteolytic processing gives rise to a soluble extracellular domain that is detected in blood plasma (at protein level). Predominantly expressed in endothelial cells and their progenitors, the angioblasts. Has been directly found in placenta and lung, with a lower level in umbilical vein endothelial cells, brain and kidney.

Subunit Structure:

Homodimer. Heterodimer with TIE1. Interacts with ANGPT1, ANGPT2 and ANGPT4. At cell-cell contacts in quiescent cells, forms a signaling complex composed of ANGPT1 plus TEK molecules from two adjoining cells. In the absence of endothelial cell-cell contacts, interaction with ANGPT1 mediates contacts with the extracellular matrix. Interacts with PTPRB; this promotes endothelial cell-cell adhesion. Interacts with DOK2, GRB2, GRB7, GRB14, PIK3R1 and PTPN11/SHP2. Colocalizes with DOK2 at contacts with the extracellular matrix in migrating cells. Interacts (tyrosine phosphorylated) with TNIP2. Interacts (tyrosine phosphorylated) with SHC1 (via SH2 domain).

Family&Domains:

The soluble extracellular domain is functionally active in angiopoietin binding and can modulate the activity of the membrane-bound form by competing for angiopoietins.

Belongs to the protein kinase superfamily. Tyr protein kinase family. Tie subfamily.

Research Fields

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Human Diseases > Immune diseases > Rheumatoid arthritis.

References

1). DPSCs treated by TGF-β1 regulate angiogenic sprouting of three-dimensionally co-cultured HUVECs and DPSCs through VEGF-Ang-Tie2 signaling. Stem Cell Research & Therapy (PubMed: 33971955) [IF=7.5]

Application: WB    Species: Human    Sample: HUVECs

Fig. 6 Conditioned media from T-DPSCs activated Tie2 signaling. a–c Western blot analysis of the expression of p-Tie2 and VE-Cadherin in HUVECs after treatment with T-DPSC-CM or Ang1 at different time points. Data are mean ± standard error for n = 3 replicates,

2). MiR-18a-5p acts as a novel serum biomarker for venous malformation and promotes angiogenesis by regulating the thrombospondin-1/P53 signaling axis. American Journal of Translational Research (PubMed: 34786057) [IF=2.2]

Application: WB    Species: Human    Sample: HUVECs

Figure 2 MiR-18a-5p promoted cell proliferation, invasion, migration and angiogenesis of HUVECs in vitro and in vivo. (A) MiR-18a-5p expression was measured via qRT-PCR in HUVECs transfected with plasmids for 48 h. (B) Cell viability was measured by CCK-8 assay in HUVECs transfected with miR-18a-5p inhibitors, miR-18a-5p mimics or corresponding NCs. (C-F) Results of transwell (C, up F), tube formation (D, middle F), and wound healing assays (E, down F) in HUVECs transfected with miR-18a-5p inhibitors, miR-18a-5p mimics or corresponding NCs. (G) Schematic diagram: establishment and treatment of the VM mouse model. (H) The phosphorylated TIE-2 level was detected by Western blot assay. (I) The lesions were harvested 2 weeks after inoculation. (J) H&E and CD31 staining of the lesions. (K) Lesions and H&E staining at 18 days after inoculation of VM model mice subjected to different treatments. (L) Growth curve of the lesion area shows the speed of VM mass growth. (M) The weight of masses excised from mice in the ectopic expression and vector groups were measured and analyzed. The relative expression fold changes in mRNA expression were calculated by the 2-ΔΔCt method. Data were obtained from three independent repeated experiments. **P

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.